Literature DB >> 98835

Pharmacological properties of diclofenac sodium and its metabolites.

R Menassé, P R Hedwall, J Kraetz, C Pericin, L Riesterer, A Sallmann, R Ziel, R Jaques.   

Abstract

Diclofenac sodium (Voltaren) is a non-steroid anti-inflammatory agent of a new chemical structure, which is animal experiments shows a high degree of anti inflammatory, analgesic, and antipyretic activity in various pharmacological models. It inhibits prostaglandin biosynthesis in vitro and in vivo, and this inhibitory effect at least partly explains the mechanism of action of the preparation. In animal experiments diclofenac sodium is characterised by a broad therapeutic range. Also, its gastrointestinal tolerability is better than that of other highly effective non-steroid anti-inflammatory agents. Two of the metabolites produced during the biotransformation of diclofenac sodium in man are also biologically active. The activity of these two metabolites, however, is very much weaker than that of unchanged diclofenac sodium and is comparable to that of phenylbutazone.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 98835     DOI: 10.3109/03009747809097211

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  39 in total

1.  Central, naloxone-reversible antinociception by diclofenac in the rat.

Authors:  R Björkman; J Hedner; T Hedner; M Henning
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Effects of systemic non-steroidal anti-inflammatory drugs on nociception during tail ischaemia and on reperfusion hyperalgesia in rats.

Authors:  L Gelgor; N Butkow; D Mitchell
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

4.  Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.

Authors:  D R H Huntjens; A Strougo; A Chain; A Metcalf; S Summerfield; D J M Spalding; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

5.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

6.  A comparison of indomethacin and diclofenac in the inhibition of experimental heterotopic new bone formation.

Authors:  O S Nilsson; H C Bauer; O Brosjö; H Törnkvist
Journal:  Int Orthop       Date:  1987       Impact factor: 3.075

7.  Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund's complete adjuvant-induced arthritic rats.

Authors:  Jing Zhang; Pei Li; Hai-fang Guo; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

8.  NSAID-induced injury of gastric epithelial cells is reversible: roles of mitochondria, AMP kinase, NGF, and PGE2.

Authors:  Amrita Ahluwalia; Neil Hoa; Michael K Jones; Andrzej S Tarnawski
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-23       Impact factor: 4.052

9.  Intravenous ketorolac vs diclofenac for analgesia after maxillofacial surgery.

Authors:  P Tarkkila; M Tuominen; P H Rosenberg
Journal:  Can J Anaesth       Date:  1996-03       Impact factor: 5.063

10.  Effective postoperative pain control by preoperative injection of diclofenac.

Authors:  E Wuolijoki; V J Oikarinen; P Ylipaavalniemi; G Hampf; M Tolvanen
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.